Frontlight ResearchEarly access
Taking peopleNo phase
Efficacy of SGLT2 Inhibitors in Adults With Sepsis
Key facts
- Who runs it
- Hospital Authority, Hong Kong
- Where
- Hong Kong3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 5 Mar 2025
- Expected to end
- 28 Feb 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Empagliflozin 10 MG
- Placebo
- Record updated
- 19 March 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Aged 18 years or above
- New onset of sepsis within 48 hours defined according to the Sepsis-3 criteria. (≥2 SOFA)
- Provision of signed and dated informed consent form from participant or surrogate
- Ability to take and adhere to oral and enteral medication regimen
- Willingness to comply
Who cannot take part
- Current or recent use of SGLT2 inhibitors (within 12wks prior to randomization)
- Treatment with another investigational drug or other interventions within 30 days prior to trial
- History of ketoacidosis
- Gastrointestinal surgery or GI absorption / malabsorption disorder
- Known allergic or hypersensitivity reactions to any SGLT2 inhibitors
- Impaired renal function
- Clinically unstable or in refractory hypotension
- Pregnancy
This trial is currently available in Hong Kong.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Goal of this clinical trial is to examine the safety and efficacy of SGLT2 inhibitors on the clinical outcomes in patients with sepsis. Main study outcomes are as follows:
Read full original descriptionShow less
(i) Primary objective is to examine the efficacy and safety of SGLT2 inhibitors on clinical outcomes in patients with sepsis.
(ii) Secondary objective is to examine the effect of SGLT2 inhibitors on inflammatory markers in patients with sepsis.
The 2 groups in the trial
- SGLT2 inhibitor empagliflozinTreatment being tested
10mg daily from recruitment to hospital discharge
Treatment: Empagliflozin 10 MG
- PlaceboPlacebo, for comparison
1 tablet daily from recruitment to hospital discharge
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Sepsis: A Feasibility Study for a Multicenter Double-Blind Randomized Placebo-Controlled Trial
- Record updated
- 19 March 2025